【摘要】贫血是慢性肾脏病(chronic kidney disease，CKD)最常见的并发症之一。心血管疾病(cardiovascular disease, CVD)是CKD 3～5 期患者的首要致死原因。CKD 贫血能够加重多系统器官的损伤,是CKD 患者伴有心血管并发症的独立危险因素。因此，加强对CKD 患者贫血的管理，有利于改善CKD 患者的心血管结局。本文主要从CKD贫血本身以及治疗等方面对CKD 贫血患者的心血管安全问题进行综述。
【Abstract】Anemia is one of the most common complications in chronic kidney disease (CKD) patients. Cardiovascular disease is a major cause of mortality in CKD patients at stage 3～5. Renal anemia can aggravate the multisystem organ damages and is an important independent risk factor for cardiovascular complications in CKD patients. Therefore, management of renal anemia must be emphasized to improve the cardiovascular outcome in CKD patients. This article reviews cardiovascular safety in CKD patients with anemia from the view point of renal anemia and its treatment.
[1] Tanaka K, Watanabe T, Takeuchi A, et al. Cardiovascular events and death in Japanese patients with chronic kidney disease[J]. Kidney International,2017,91(1):227-234.
[2] Gansevoort R T D, Correa-Rotter R P, Hemmelgarn B R P, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention[J]. Lancet,2013,382(9889):339-352.
[3] 马春园，何樟秀，周阳，等。慢性肾脏病3 ～ 5D期贫血状况的单中心横断面调查[J]。中国血液净化,2017,17(4):205-210。
[4] Zhang L, Zuo L, Yu F, et al. China Kidney Disease Network (CK-NET) 2015 Annual Data Report[J]. Kidney Int Suppl,2019,9(1):e1–e81.
[5] Kim-Mitsuyama S, Soejima H, Yasuda O, et al. Anemia is an independent risk factor for cardiovascular and renal events in hypertensive outpatients with well-controlled blood pressure: a subgroup analysis of the ATTEMPT-CVD randomized trial[J]. Hypertension Research,2019,42(6):883-891.
[6] Foley R N, Parfrey P S, Harnett J D, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease[J]. American Journal of Kidney Diseases,1996,28(1):53-61.
[7] Tanaka T, Eckardt K. HIF Activation Against CVD in CKD: Novel Treatment Opportunities[J]. Seminars in Nephrology,2018,38(3):267-276.
[8] Singh A K, Szczech L, Tang K L, et al. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease[J]. The New England Journal of Medicine,2006,355(20):2085-2098.
[9] Mccullough P A, Barnhart H X, Inrig J K, et al. Cardiovascular Toxicity of Epoetin-Alfa in Patients with Chronic Kidney Disease[J]. American Journal of Nephrology,2013,37(6):549-558.
[10] Zhang Y, Thamer M, Stefanik K, et al. Epoetin requirements predict mortality in hemodialysis patients[J]. American Journal of Kidney Diseases,2004,44(5):866-876.
[11] Vaziri N D. Safety Issues in Iron Treatment in CKD[J]. Seminars in Nephrology,2016,36(2):112-118.
[12] Agarwal R, Kusek J W, Pappas M K. A randomized trial of intravenous and oral iron in chronic kidney disease[J]. Kidney International,2015,88(4):905-914.
[13] Tangri N, Miskulin D C, Zhou J, et al. Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study[J]. Nephrol Dial Transplant,2015,30(4):667-675.
[14] H?lscher M, Silter M, Krull S, et al. Cardiomyocyte-specific Prolyl-4-hydroxylase Domain 2 Knock Out Protects from Acute Myocardial Ischemic Injury[J]. Journal of Biological Chemistry,2011,286(13):11185-11194.
[15] Chaudhari S M, Sluimer J C, Koch M, et al. Deficiency of HIF1α in Antigen-Presenting Cells Aggravates Atherosclerosis and Type 1 T-Helper Cell Responses in Mice[J]. Arteriosclerosis, Thrombosis, and Vascular Biology,2015,35(11):2316-2325.
[16] Zhang X, Zhang Y, Wang P, et al. Adipocyte Hypoxia-Inducible Factor 2α Suppresses Atherosclerosis by Promoting Adipose Ceramide Catabolism[J]. Cell Metabolism,2019,30(5):937-951.
[17] Hwang S, Nguyen A D, Jo Y, et al. Hypoxia-inducible factor 1alpha activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver[J]. J Biol Chem,2017,292(22):9382-9393.
[18] Locatelli F, Fishbane S, Block G A, et al. Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients[J]. American Journal of Nephrology,2017,45(3):187-199.
[19] Akizawa T, Tsubakihara Y, Nangaku M, et al. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects[J]. American Journal of Nephrology,2017,45(2):127-135.
[20] Martin E R, Smith M T, Maroni B J, et al. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease[J]. American Journal of Nephrology,2017,45(5):380-388.
